SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Eiger BioPharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 9, 2023 - (NASDAQ: EIGR)

NEW YORK, Jan. 4, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Eiger BioPharmaceuticals, Inc..

Shareholders who purchased shares of EIGR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.

CONTACT US HERE:
https://securitiesclasslaw.com/securities/eiger-biopharmaceuticals-inc-loss-submission-form/?id=35256&from=4

CLASS PERIOD: March 10, 2021 to October 4, 2022

ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) defendants overstated Eiger's clinical and regulatory drug development expertise; (ii) defendants failed to properly assess, and/or ignored issues with, the design of the TOGETHER study and its ability to support the Emergency Use Authorization ("EUA") for the Company's product candidate, peginterferon lambda ; (iii) there were issues with the conduct of the TOGETHER study and/or the TOGETHER study was not properly designed for the peginterferon lambda EUA in the current context of the pandemic; (iv) as a result, the U.S. Food and Drug Administration was unlikely to approve the submission of a peginterferon lambda EUA; (v) as a result of all the foregoing, peginterferon lambda's regulatory and commercial prospects for the treatment of COVID-19 were overstated; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.

DEADLINE: January 9, 2023 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/eiger-biopharmaceuticals-inc-loss-submission-form/?id=35256&from=4

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of EIGR during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is January 9, 2023. There is no cost or obligation to you to participate in this case.

WHY GROSS LAW FIRM? The Gross Law Firm is nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: [e-mail]
Phone: [phone]

View original content:https://www.prnewswire.com/news-releases/shareholder-alert-the-gross-law-firm-notifies-shareholders-of-eiger-biopharmaceuticals-inc-of-a-class-action-lawsuit-and-a-lead-plaintiff-deadline-of-january-9-2023--nasdaq-eigr-301712990.html

SOURCE The Gross Law Firm

Copyright 2023 PR Newswire